CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6432 result(s)

romosozumab (Evenity )

Last Updated: June 11, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: romosozumab
Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

  • Brand Name: Evenity
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0676-000
  • Project Status: Active
  • Submission Type: Initial

incobotulinumtoxin A (Xeomin)

Last Updated: June 11, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: incobotulinumtoxinA
Indications: ​For the treatment of chronic sialorrhea associated with neurological disorders in adults.

  • Brand Name: Xeomin
  • Manufacturer: Merz Pharmaceuticals GMBH
  • Project Number: SR0678-000
  • Project Status: Active
  • Submission Type: Initial

liraglutide (Saxenda)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Active
  • Submission Type: Initial

lorlatinib (Lorbrena)

Last Updated: June 10, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: lorlatinib
Indications: Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)

  • Brand Name: Lorbrena
  • Manufacturer: Pfizer Canada
  • Project Number: PC0249-000
  • Project Status: Pending
  • Submission Type: Initial

luspatercept (Reblozyl )

Last Updated: June 9, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: Reblozyl (luspatercept for injection) is indicated for:  the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.  the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC units over 8 weeks resulting from very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc., a Bristol Myers Squibb company
  • Project Number: SR0670-000
  • Project Status: Active
  • Submission Type: Initial

upadacitinib (Rinvoq)

Last Updated: June 9, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: upadacitinib
Indications: Rinvoq is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs.. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

  • Brand Name: Rinvoq
  • Manufacturer: AbbVie
  • Project Number: SR0658-000
  • Project Status: Active
  • Submission Type: Initial

brexucabtagene autoleucel (Tecartus)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: brexucabtagene autoleucel
Indications: For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.

  • Brand Name: Tecartus
  • Manufacturer: Gilead Sciences Canada Inc.
  • Project Number: PG0219-000
  • Project Status: Active
  • Submission Type: Initial

zanubrutinib (Brukinsa )

Last Updated: June 9, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: zanubrutinib
Indications: For the treatment of patients with Waldenström’s macroglobulinemia (WM)

  • Brand Name: Brukinsa
  • Manufacturer: BeiGene, Ltd.
  • Project Number: PC0248-000
  • Project Status: Active
  • Submission Type: Initial

dinutuximab (Unituxin)

Last Updated: March 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dinutuximab
Indications: For the treatment of high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor.

  • Brand Name: Unituxin
  • Manufacturer: United Therapeutics Corp.
  • Project Number: PC0222-000
  • Project Status: Active
  • Submission Type: Initial

encorafenib and binimetinib (Braftovi and Mektovi)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib and binimetinib
Indications: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

  • Brand Name: Braftovi and Mektovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0232-000
  • Project Status: Active
  • Submission Type: Initial